Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 김윤환 | * |
dc.date.accessioned | 2018-08-22T16:30:04Z | - |
dc.date.available | 2018-08-22T16:30:04Z | - |
dc.date.issued | 2018 | * |
dc.identifier.issn | 2005-0380 | * |
dc.identifier.issn | 2005-0399 | * |
dc.identifier.other | OAK-22852 | * |
dc.identifier.uri | https://dspace.ewha.ac.kr/handle/2015.oak/245422 | - |
dc.description.abstract | Objective: To determine whether drospirenone/estradiol (DRSP/E2) has an adverse effect on clinical outcomes in surgically staged International Federation of Gynecology and Obstetrics (FIGO) stage I/II endometrial cancer (EC) patients. Methods: In a retrospective case-controlled study, 58 women with EC who had received DRSP/E2 postoperatively were compared with 116 women who had not. And, oncologic safety of postoperative hormone therapy with DRSP/E2 in EC survivors were compared between the 2 groups after propensity score matching using a logistic regression model. Results: The median ages were 47.7 years and 53.6 years for the study and the control groups, respectively (p<0.001). The study group had similar parity (p=0.71), lower body mass index (p=0.03) and more premenopausal women (p<0.001) than the control group. The stages were completely matched. The grades (p=0.42), lymphovascular space invasion (p=0.23), preoperative cancer antigen 125 (CA125) level (p=0.89), and hormone receptor status (p=0.07) were similar in both groups. The median tumor diameter was statistically larger in the study group than in the control group (p<0.001). Both group received similar adjuvant therapy (p=0.80). In the propensity matching, only hormone receptor status was significantly different (p=0.03). In the univariate analysis, only stage was significantly associated with disease-free survival (DFS) and there was no variable associated with overall survival (OS). And, there was no significant factor identified in multivariate analysis. The difference in the DFS (p=0.63) and in the OS (p=0.32) was not significant. The same results were obtained after propensity score matching. Conclusion: Postoperative hormone therapy with DRSP/E2 in EC survivors did not increase recurrence or the death rate. | * |
dc.language | English | * |
dc.publisher | KOREAN SOC GYNECOLOGY ONCOLOGY & | * |
dc.publisher | COLPOSCOPY | * |
dc.subject | Endometrial Neoplasms | * |
dc.subject | Hormone Replacement Therapy | * |
dc.subject | Drospirenone | * |
dc.subject | Estradiol | * |
dc.title | The influence of hormone therapy with drospirenone-estradiol on endometrioid type endometrial cancer patients | * |
dc.type | Article | * |
dc.relation.issue | 5 | * |
dc.relation.volume | 29 | * |
dc.relation.index | SCIE | * |
dc.relation.index | SCOPUS | * |
dc.relation.index | KCI | * |
dc.relation.journaltitle | JOURNAL OF GYNECOLOGIC ONCOLOGY | * |
dc.identifier.doi | 10.3802/jgo.2018.29.e72 | * |
dc.identifier.wosid | WOS:000439890800011 | * |
dc.author.google | Lim, Soyi | * |
dc.author.google | Kim, Yun Hwan | * |
dc.author.google | Lee, Kwang-Beom | * |
dc.author.google | Lee, Jong-Min | * |
dc.contributor.scopusid | 김윤환(55763947200) | * |
dc.date.modifydate | 20240220115825 | * |